Outset Medical/$OM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Outset Medical
Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
Ticker
$OM
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
354
ISIN
US6901452069
Website
Outset Medical Metrics
BasicAdvanced
$364M
-
-$26.02
1.90
-
Price and volume
Market cap
$364M
Beta
1.9
52-week high
$21.98
52-week low
$7.85
Average daily volume
443K
Financial strength
Current ratio
8.373
Quick ratio
6.601
Long term debt to equity
56.7
Total debt to equity
57.791
Interest coverage (TTM)
-4.18%
Profitability
EBITDA (TTM)
-84.088
Gross margin (TTM)
36.16%
Net profit margin (TTM)
-98.74%
Operating margin (TTM)
-78.24%
Effective tax rate (TTM)
-0.39%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-17.41%
Return on equity (TTM)
-86.53%
Valuation
Price to revenue (TTM)
0.779
Price to book
2.19
Price to tangible book (TTM)
2.19
Price to free cash flow (TTM)
-0.926
Free cash flow yield (TTM)
-108.02%
Free cash flow per share (TTM)
-2,216.54%
Growth
Revenue change (TTM)
-7.84%
Earnings per share change (TTM)
-48.49%
3-year revenue growth (CAGR)
1.50%
3-year earnings per share growth (CAGR)
-16.42%
Bulls say / Bears say
Outset Medical secured a $294 million financing package, including a $169 million private placement and a $125 million term loan, expected to fund operations through cash flow breakeven. (stocktitan.net)
The company reported fourth-quarter 2024 revenue of $29.5 million, exceeding Wall Street expectations and indicating strong demand for its Tablo hemodialysis systems. (massdevice.com)
Outset Medical's Tablo installed base grew by 10% in 2024, reaching nearly 6,000 consoles, demonstrating increasing market adoption. (massdevice.com)
Outset Medical received a warning letter from the FDA in July 2023, leading to a pause in shipments of its TabloCart with Prefiltration and negatively impacting revenue. (healio.com)
The company faced a potential Nasdaq delisting in September 2024 due to its stock trading below $1.00 for 30 consecutive days, reflecting investor concerns. (investing.com)
Major investors like Morgan Stanley and JPMorgan Chase significantly reduced their positions in Outset Medical in 2024, indicating decreased confidence in the company's prospects. (globenewswire.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Outset Medical News
AllArticlesVideos
Outset Medical to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewsWire·1 month ago
Outset Medical Appoints Renee Gaeta as Chief Financial Officer
GlobeNewsWire·1 month ago
Outset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of Directors
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Outset Medical stock?
Outset Medical (OM) has a market cap of $364M as of July 11, 2025.
What is the P/E ratio for Outset Medical stock?
The price to earnings (P/E) ratio for Outset Medical (OM) stock is 0 as of July 11, 2025.
Does Outset Medical stock pay dividends?
No, Outset Medical (OM) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Outset Medical dividend payment date?
Outset Medical (OM) stock does not pay dividends to its shareholders.
What is the beta indicator for Outset Medical?
Outset Medical (OM) has a beta rating of 1.9. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.